Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CVRX | Common Stock | Conversion of derivative security | +1.51K | +4.73% | 33.3K | Jul 2, 2021 | See Footnote | F2, F4 | ||
transaction | CVRX | Common Stock | Conversion of derivative security | +13K | +38.96% | 46.3K | Jul 2, 2021 | See Footnote | F2, F4 | ||
transaction | CVRX | Common Stock | Conversion of derivative security | +14.9K | +32.22% | 61.2K | Jul 2, 2021 | See Footnote | F2, F4 | ||
transaction | CVRX | Common Stock | Conversion of derivative security | +8.38K | +13.69% | 69.6K | Jul 2, 2021 | See Footnote | F2, F4 | ||
transaction | CVRX | Common Stock | Conversion of derivative security | +27.3K | +39.29% | 96.9K | Jul 2, 2021 | See Footnote | F2, F4 | ||
transaction | CVRX | Common Stock | Conversion of derivative security | +636K | +655.73% | 733K | Jul 2, 2021 | See Footnote | F3, F4 | ||
transaction | CVRX | Common Stock | Purchase | $4.95M | +275K | +37.54% | $18.00 | 1.01M | Jul 2, 2021 | See Footnote | F1, F5 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CVRX | Series B-2 Preferred Stock | Conversion of derivative security | $0 | -59.5K | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 1.51K | See Footnote | F2, F4 | |
transaction | CVRX | Series C-2 Preferred Stock | Conversion of derivative security | $0 | -513K | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 13K | See Footnote | F2, F4 | |
transaction | CVRX | Series D-2 Preferred Stock | Conversion of derivative security | $0 | -590K | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 14.9K | See Footnote | F2, F4 | |
transaction | CVRX | Series E-2 Preferred Stock | Conversion of derivative security | $0 | -331K | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 8.38K | See Footnote | F2, F4 | |
transaction | CVRX | Series F-2 Preferred Stock | Conversion of derivative security | $0 | -1.08M | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 27.3K | See Footnote | F2, F4 | |
transaction | CVRX | Series G Preferred Stock | Conversion of derivative security | $0 | -10.1M | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 636K | See Footnote | F3, F4 |
GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering. |
F2 | The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
F3 | The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
F4 | The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). |
F5 | The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person. |